Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Share-based Compensation (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Share-based Compensation for 6 consecutive years, with $411737.0 as the latest value for Q4 2021.

  • Quarterly Share-based Compensation fell 24.19% to $411737.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2021, down 31.29% year-over-year, with the annual reading at $186287.0 for FY2025, 67.43% down from the prior year.
  • Share-based Compensation for Q4 2021 was $411737.0 at ENDRA Life Sciences, up from $327799.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $546040.0 in Q2 2020, with the low at $29698.0 in Q1 2017.
  • Average Share-based Compensation over 5 years is $365859.5, with a median of $365571.5 recorded in 2018.
  • Peak annual rise in Share-based Compensation hit 2972.07% in 2017, while the deepest fall reached 62.04% in 2017.
  • Over 5 years, Share-based Compensation stood at $402443.0 in 2017, then fell by 23.53% to $307750.0 in 2018, then grew by 23.23% to $379247.0 in 2019, then soared by 43.21% to $543120.0 in 2020, then dropped by 24.19% to $411737.0 in 2021.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $411737.0, $327799.0, and $383087.0 for Q4 2021, Q3 2021, and Q2 2021 respectively.